Literature DB >> 25265997

Serum TNF-α, IL-10 and IL-2 in schizophrenic patients before and after treatment with risperidone and clozapine.

Abolghasem Ajami1, Farshideh Abedian, Seyyed Hamzeh Hosseini, Elahe Akbarian, Reza Alizadeh-Navaei, Mehrdad Taghipour.   

Abstract

BACKGROUND: Schizophrenia is a disorder of the executive function of both sensory and central nervous system. Recent studies suggest that immune mechanisms play a role in the pathophysiology of this disease. The variations in cytokine concentrations have been associated with psychopathology and treatment of schizophrenia.
OBJECTIVE: To investigate the changes in serum concentrations of TNF-α, IL-10, and IL-2 in schizophrenic patients before and 40 days after treatment.
METHODS: In a case-control study, 26 schizophrenic patients and 26 healthy individuals as a control group were enrolled. PANSS scale questionnaire was used for diagnosis and assessing the severity of the disease. All patients were then treated with risperidone or clozapine for 40 days. Serum concentrations of TNF-α, IL-10 and IL-2 were measured by ELISA before and after treatment in both groups. Paired t-test and Independent t-test were used for comparison of data.
RESULTS: Comparison of TNF-α and IL-10 concentrations in patients before and after treatment revealed a significance decrease of TNF-α and increase of IL-10 concentrations (p=0.002, and p=0.008, respectively). Serum concentrations of IL-2 were lower than the detection limit of assay and were not detectable. In comparison with healthy controls, serum concentrations of TNF-α in schizophrenic patients were higher, while IL-10 concentrations were lower before treatment although the differences were not significant (p=0.291 and p=0.375, respectively). There was no correlation between cytokine concentrations and the positive and negative scale (PANSS). Also no significant difference in the admission, relapses, and duration of illness before and after treatment was observed.
CONCLUSIONS: Increase of TNF-α and decrease of IL-10 may have an important role in psychopathology of schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25265997     DOI: IJIv11i3A6

Source DB:  PubMed          Journal:  Iran J Immunol        ISSN: 1735-1383            Impact factor:   1.603


  13 in total

Review 1.  Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine.

Authors:  Domenico De Berardis; Gabriella Rapini; Luigi Olivieri; Domenico Di Nicola; Carmine Tomasetti; Alessandro Valchera; Michele Fornaro; Fabio Di Fabio; Giampaolo Perna; Marco Di Nicola; Gianluca Serafini; Alessandro Carano; Maurizio Pompili; Federica Vellante; Laura Orsolini; Giovanni Martinotti; Massimo Di Giannantonio
Journal:  Ther Adv Drug Saf       Date:  2018-02-06

2.  Evaluating the Hypothesis That Schizophrenia Is an Inflammatory Disorder.

Authors:  Brian J Miller; David R Goldsmith
Journal:  Focus (Am Psychiatr Publ)       Date:  2020-11-05

Review 3.  Towards an Immunophenotype of Schizophrenia: Progress, Potential Mechanisms, and Future Directions.

Authors:  Brian J Miller; David R Goldsmith
Journal:  Neuropsychopharmacology       Date:  2016-09-22       Impact factor: 7.853

4.  Tumor necrosis factor-α and -β genetic polymorphisms as a risk factor in Saudi patients with schizophrenia.

Authors:  Saeed Kadasah; Misbahul Arfin; Sadaf Rizvi; Mohammed Al-Asmari; Abdulrahman Al-Asmari
Journal:  Neuropsychiatr Dis Treat       Date:  2017-04-12       Impact factor: 2.570

5.  A Meta-analysis of Immune Parameters, Variability, and Assessment of Modal Distribution in Psychosis and Test of the Immune Subgroup Hypothesis.

Authors:  Toby Pillinger; Emanuele F Osimo; Stefan Brugger; Valeria Mondelli; Robert A McCutcheon; Oliver D Howes
Journal:  Schizophr Bull       Date:  2019-09-11       Impact factor: 9.306

6.  Blood-brain barrier and intestinal epithelial barrier alterations in autism spectrum disorders.

Authors:  Maria Fiorentino; Anna Sapone; Stefania Senger; Stephanie S Camhi; Sarah M Kadzielski; Timothy M Buie; Deanna L Kelly; Nicola Cascella; Alessio Fasano
Journal:  Mol Autism       Date:  2016-11-29       Impact factor: 7.509

7.  Pretreatment With Risperidone Ameliorates Systemic LPS-Induced Oxidative Stress in the Cortex and Hippocampus.

Authors:  Md Mamun Al-Amin; Md Faiyad Rahman Choudhury; Al Saad Chowdhury; Tahsinur Rahman Chowdhury; Preeti Jain; Mohsin Kazi; Musaed Alkholief; Sultan M Alshehri; Hasan Mahmud Reza
Journal:  Front Neurosci       Date:  2018-06-08       Impact factor: 4.677

8.  Study of Novel Autoantibodies in Schizophrenia.

Authors:  Ruth Whelan; David St Clair; Colette J Mustard; Philomena Hallford; Jun Wei
Journal:  Schizophr Bull       Date:  2018-10-17       Impact factor: 9.306

9.  Kinetics of Cytokine Levels during Antipsychotic Treatment in Schizophrenia: A Meta-Analysis.

Authors:  Bruno Romeo; Marine Brunet-Lecomte; Catherine Martelli; Amine Benyamina
Journal:  Int J Neuropsychopharmacol       Date:  2018-09-01       Impact factor: 5.176

Review 10.  Immunoendocrine Peripheral Effects Induced by Atypical Antipsychotics.

Authors:  Samantha Alvarez-Herrera; Raúl Escamilla; Oscar Medina-Contreras; Ricardo Saracco; Yvonne Flores; Gabriela Hurtado-Alvarado; José Luis Maldonado-García; Enrique Becerril-Villanueva; Gilberto Pérez-Sánchez; Lenin Pavón
Journal:  Front Endocrinol (Lausanne)       Date:  2020-04-21       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.